Introduction {#s1}
============

The programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway plays a critical role in tumor immune response. Anti-PD-1 antibodies such as nivolumab and pembrolizumab are thus in wide use for the treatment of various cancers, including advanced melanoma ([@B1], [@B2]). Nivolumab significantly prolongs survival in patients with metastatic melanoma ([@B1]), and co-administration with ipilimumab also leads to improved outcomes ([@B1]--[@B3]). Ipilimumab is a fully humanized immunoglobulin (Ig)G1 monoclonal antibody that blocks cytotoxic T-lymphocyte antigen (CTLA-4) to activate and increase T cells, and suppress the function of regulatory T cells (Tregs) ([@B4]). Previous reports have suggested ipilimumab is useful for treating advanced melanoma, particularly in combination with other anti-melanoma reagents ([@B1]--[@B3], [@B5]). Moreover, combination therapy using nivolumab and ipilimumab reportedly increases the response rate for untreated metastasis of melanoma to the brain ([@B6]). However, the efficacy of ipilimumab in patients with nivolumab-resistant melanoma is extremely low after objective tumor progression ([@B7]). Because both co-administration of nivolumab and ipilimumab and sequential administration of nivolumab and ipilimumab with a planned switch leads to a high frequency of immune-related adverse events (irAEs) in patients with advanced melanoma ([@B1], [@B3]), determining the efficacy of nivolumab monotherapy before the planned switch from nivolumab to ipilimumab is important.

Tumor-associated macrophages (TAMs) are characterized by their heterogeneity and plasticity, and may be functionally reprogrammed to polarized phenotypes by exposure to cancer-related factors, stromal factors, or infection, leading to the production of various chemokines that play significant roles in maintaining the tumor microenvironment ([@B8]--[@B13]). Because PD-1 expression in TAMs is one of the key factors in M2 macrophage polarization ([@B14]), administration of an anti-PD1 antibody might repolarize TAMs, leading to TAM activation in melanoma patients. Because the main population of TAMs in skin cancer is CD163^+^ M2 macrophages, and soluble cluster of differentiation 163 (sCD163) is a TAM marker that appears in the serum as a result of proteolytic shedding ([@B15]), we hypothesized that serum sCD163 may offer a predictive marker for the efficacy of nivolumab in the early stage of disease. This study analyzed serum levels of sCD163 in 59 cases of advanced cutaneous melanoma and 16 cases of advanced mucosal melanoma treated with nivolumab.

Patients and methods {#s2}
====================

Ethics statement for human experiments
--------------------------------------

The protocol for this human study was approved by the ethics committee of Tohoku University Graduate School of Medicine, Sendai, Japan (Permit No: 2017-1-064). All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.

Patients
--------

Data from patients treated with nivolumab were collected from eight clinical sites in Japan. Patients were eligible if they had unresectable stage III melanoma, the tumor was resectable but the patient had declined resection, or if the patient had stage IV melanoma with accessible cutaneous, subcutaneous, and/or nodal lesions (staging was performed according to the AJCC Staging Manual, 7th edition, 2011). All patients received 2 mg/kg of nivolumab followed by a 3-week rest period or 3 mg/kg of nivolumab followed by 2 weeks of rest, both of which are approved dosing schedules in Japan. Serum from patients was obtained on days 0 and 42.

Serum levels of sCD163
----------------------

On days 0 and 42 after nivolumab administration, we stored the serum and analyzed serum levels of soluble sCD163 by enzyme-linked immunoassay (ELISA) according to the protocol provided by the manufacturer (catalog number DY1607; R&D Systems, Minneapolis, MN). Data from each donor were obtained as the mean of duplicate assays. Serum levels on day 42 were compared to baseline (day 0) and statistically analyzed.

Statistical methods
-------------------

Receiver operating characteristic (ROC) curves were applied to calculate cut-off values for serum levels of sCD163 and areas under the curve (AUCs). Cut-offs were determined using Youden\'s index ([@B16]) (sensitivity + specificity −1) to determine the point of maximum index value. ROC curves were established to evaluate serum levels of sCD163 in patients administered nivolumab. For a single comparison between two groups, the Mann-Whitney U-test was used. Levels of significance were set at p \< 0.01. All statistical analyses were performed using JMP version 14.1 software (SAS Institute, Tokyo, Japan).

Results {#s3}
=======

Patients
--------

We collected data from 75 melanoma patients treated with nivolumab, including 59 patients with cutaneous melanoma (Table [1](#T1){ref-type="table"}) and 16 patients with non-cutaneous (e.g., digestive tract, vagina, nasal cavity) melanoma (Table [2](#T2){ref-type="table"}). Mean patient age was 68.0 years for cutaneous melanoma (range, 31--93 years) and 66.0 years for non-cutaneous melanoma (range, 54--82 years). The percentages of male patients with cutaneous and non-cutaneous melanoma were 57.6 and 56.3%, respectively. The most common primary tumor site was the extremities (55.9%), followed by the head and neck (15.3%), trunk (11.9%), mucosal origin (8.5%), and unknown origin (8.5%).

###### 

Characteristics and serum levels of sCD163 in patients with cutaneous melanoma.

           **Age (y)**   **Sex**   **Location**         **Body weight (kg)**   **Prior systemic therapy**   **Efficacy at 3 months**   **Increase of sCD163**   **Change ratio of sCD163 (%)**
  -------- ------------- --------- -------------------- ---------------------- ---------------------------- -------------------------- ------------------------ --------------------------------
  No. 1    61--70        M         Extremities          63.2                   DAV+IFN-β                    PR                         11.556                   149
  No. 2    61--70        M         Extremities          48                     --                           PR                         50.8525                  227.8
  No. 3    81--90        F         Extremities          48.7                   DPCP                         PR                         12.676                   152.7
  No. 4    61--70        M         Extremities          70.4                   DAV+IFN-β                    PR                         13.27122                 146.2
  No. 5    61--70        M         Extremities          58.5                   DAV+IFN-β                    PR                         7.17709                  127
  No. 6    61--70        M         Lip                  69.8                   DAV+IFN-β                    PR                         5.834                    123.1
  No. 7    71--80        M         Trunk                59.4                   --                           PR                         21.49956                 133.4
  No. 8    71--80        F         Extremities          68                     --                           PR                         −12.9704                 81.6
  No. 9    31--40        F         Extremities          55.4                   DTIC+IFN-β                   PR                         24.5042321               189.5
  No. 10   71--80        M         Extremities          61.2                   --                           PR                         3.36944                  109.5
  No. 11   51--60        F         Extremities          41.7                   --                           CR                         2.109187                 170.7
  No. 12   81--90        M         Unknown              68.3                   --                           PR                         3.07118                  111.3
  No. 13   71--80        F         Extremities          50.1                   IFN-α                        PR                         35.7011169               158.5
  No. 1    51--60        M         Trunk                68.7                   --                           SD                         1.5625                   107.5
  No. 2    31--40        F         Extremities          60.8                   CBDCA+PTX                    PD                         −9.6755                  82.4
  No. 3    61--70        M         Trunk                62                     DTIC+IFN-β                   PD                         2.884                    109.6
  No. 4    81--90        F         Extremities          44.9                   IFN-α                        PD                         −0.333                   98.7
  No. 5    71--80        M         Head and neck        59.2                   IFN-β                        SD                         0.998                    103.6
  No. 6    81--90        F         Trunk                41.9                   IFN-β                        PD                         6.76453                  116.9
  No. 7    91--100       M         Extremities          55                     IFN-β                        PD                         4.02405                  113
  No. 8    71--80        M         Extremities          85.9                   IFN-β                        SD                         −5.10307                 89.9
  No. 9    31--40        M         Extremities          73                     TMZ                          PD                         −16.806                  67.8
  No. 10   61--70        M         Extremities          55                     anti-CCR4 Abs                PD                         2.706                    115.4
  No. 11   61--70        F         Extremities          66.3                   DAV+IFNβ                     PD                         0.653                    103.4
  No. 12   61--70        M         Head and neck        55                     DTIC                         PD                         −0.094                   99.6
  No. 13   61--70        M         Extremities          115.4                  DAV+IFN-β                    SD                         0.177                    100.5
  No. 14   61--70        M         Extremities          77.6                   IFN-β                        PD                         −61.59461                35.5
  No. 15   81--90        F         Unknown              47.8                   --                           SD                         −6.54815                 86.5
  No. 16   71--80        M         Extremities          54.4                   IFN-β                        SD                         −4.74553                 80.8
  No. 17   61--70        F         Trunk                46.5                   --                           PD                         17.3346                  140.4
  No. 18   71--80        M         Extremities          53.7                   --                           PD                         −1.595225                93
  No. 19   51--60        F         Head and neck        49.2                   DTIC+IFN-β                   PD                         5.457395                 115.9
  No. 20   31--40        M         Trunk                78.8                   IFN-α                        SD                         −12.615365               53.7
  No. 21   61--70        F         Trunk                48.8                   IFN-β                        PD                         −1.7178157               96.2
  No. 22   31--40        F         Head and neck        52.3                   IFN-β                        PD                         3.88229                  120.1
  No. 23   71--80        F         External genitalia   59.1                   --                           SD                         −3.34502                 92.1
  No. 24   71--80        F         External genitalia   53.4                   IFN-β                        SD                         −7.38773                 70.5
  No. 25   61--70        F         Extremities          47.0                   --                           PD                         −4.11263                 64
  No. 26   61--70        M         Unknown              53.6                   --                           PD                         −3.78005                 75.6
  No. 27   61--70        F         Extremities          60.9                   IFN-β                        PD                         −0.54818                 95.9
  No. 28   61--70        F         Head and neck        41.6                   IFN-α                        PD                         −1.456879                80.8
  No. 29   71--80        M         Trunk                56                     --                           PD                         −0.71335                 77.2
  No. 30   41--50        F         External genitalia   69.2                   --                           PD                         −0.170996                94.4
  No. 31   71--80        F         Extremities          53.3                   --                           PD                         −0.682222                85.8
  No. 32   61--70        M         Extremities          61                     --                           SD                         2.202349                 183.2
  No. 33   71--80        M         Unknown              55                     --                           PD                         0.328041                 107.4
  No. 34   61--70        F         Extremities          68                     --                           SD                         0.228017                 106.3
  No. 35   71--80        M         Extremities          59.3                   IFN-β                        SD                         −1.7178157               96.2
  No. 36   61--70        M         Unknown              49.1                   --                           PD                         0.428485                 117.4
  No. 37   61--70        M         Head and neck        61                     --                           SD                         0.164125                 110.7
  No. 38   41--50        F         External genitalia   56                     --                           SD                         1.268748                 247.2
  No. 39   71--80        F         Extremities          47                     --                           PD                         −0.721186                86.1
  No. 40   41--50        M         Head and neck        103                    DTIC                         PD                         −0.111639                98
  No. 41   61--70        M         Extremities          73                     IFN-β                        SD                         0.421323                 113.8
  No. 42   31--40        M         Extremities          63.5                   --                           PD                         0.9897167                102.1
  No. 43   71--80        F         Extremities          66.2                   --                           SD                         7.3643392                116.5
  No. 44   71--80        M         Extremities          63.7                   IFN-β                        PD                         −7.0989841               91.9
  No. 45   71--80        M         Head and neck        57.4                   --                           PD                         −0.5957191               98.4
  No. 46   41--50        M         Extremities          62.7                   IFN-β                        PD                         2.4247196                105.7

*CBDCA, carboplatin; PTX, paclitaxel; DTIC; dacarbazine; TMZ, temozolomide; DAV, dacarbazine + nimustine hydrochloride + vincristine. Serum level changes of sCD163 from each patient (n = 59) between day 42 and day 0 were examined by ELISA. Data for each donor represent the means of duplicate assays*.

###### 

Characteristics and serum levels of sCD163 in patients with non-cutaneous melanoma.

           **Age (y)**   **Sex**   **Location**     **Body weight (kg)**   **Prior systemic therapy**   **Efficacy at 3 months**   **Increase of sCD163**   **Change ratio of sCD163 (%)**
  -------- ------------- --------- ---------------- ---------------------- ---------------------------- -------------------------- ------------------------ --------------------------------
  No. 1    61--70        M         Digestive duct   62                     --                           PR                         −0.444523                81.5
  No. 2    61--70        F         Palate           52.8                   --                           PR                         −0.799493                77.6
  No. 3    61--70        M         Paranasal        71                     --                           PR                         −1.803397                62.8
  No. 4    61--70        F         Vagina           52.5                   --                           PR                         0.469173                 114.6
  No. 1    61--70        M         Vagina           53.4                   --                           SD                         −17.52087                78.7
  No. 2    61--70        M         Vagina           80.4                   --                           PD                         49.95895                 134.6
  No. 3    51--60        F         Conjunctiva      84                     --                           SD                         8.27076                  115.4
  No. 4    81--90        M         Digestive duct   49.5                   --                           PD                         19.6379                  158.1
  No. 5    61--70        F         Digestive duct   49.3                   --                           SD                         20.26377                 155.2
  No. 6    71--80        F         Vagina           50.1                   --                           PD                         28.525981                192.1
  No. 7    61--70        M         Nasal cavity     47.2                   DTIC                         PD                         17.0558                  132.6
  No. 8    61--70        F         Vagina           53.1                   DAV + IFN-β                  PD                         −17.787                  64.2
  No. 9    61--70        M         Paranasal        56                     DTIC                         PD                         0.16109                  132.6
  No. 10   51--60        M         Palate           52.9                   --                           PD                         1.086                    107.3
  No. 11   71--80        M         Nasal cavity     53.1                   DAV + IFN-β                  SD                         2.52838                  107.6
  No. 12   71--80        F         Nasal cavity     53                     --                           SD                         −0.345647                89.4

*DAV, dacarbazine + nimustine hydrochloride + vincristine; DTIC, dacarbazine Serum level changes of sCD163 from each patient (n = 16) between day 42 and day 0 were examined by ELISA. Data for each donor represent the means of duplicate assays*.

Efficacy of nivolumab at 3 months after first administration
------------------------------------------------------------

Among patients with cutaneous melanoma, complete response (CR) was seen in 1 patient (1.7%; 95% confidence interval \[CI\], 0--3.4%), partial response (PR) in 12 patients (20.3%; 95%CI, 0--40.6%), stable disease (SD) in 16 patients (27.1%; 95%CI, 0--54.2%), and progressive disease (PD) in 29 patients (49.2%; 95%CI, 0--98.4%). The objective response rate (ORR) at 3 months after first administration was thus 22.0% (95%CI, 0--44.0%). Tumor responses of individual patients are listed in Table [1](#T1){ref-type="table"}. Among patients with mucosal melanoma, PR was seen in 4 patients (25.0%; 95%CI, 0--50.0%), SD in 5 patients (31.3%; 95%CI, 0--62.6%), and PD in 7 patients (43.8%; 95%CI, 0--87.6%). The ORR at 3 months after first administration was thus 25.0% (95%CI, 0--50.0%). Tumor responses of individual patients are listed in Table [2](#T2){ref-type="table"}.

Serum levels of sCD163
----------------------

To determine whether serum levels of sCD163 may predict early response in melanoma patients treated with nivolumab, we evaluated levels in 75 patients with advanced melanoma treated using nivolumab (Supplemental Figure [1](#SM1){ref-type="supplementary-material"}). Compared to baseline (day 0), serum levels of sCD163 at day 42 were significantly increased in the group showing objective response (*p* \< 0.0001; Figure [1A](#F1){ref-type="fig"}) among patients with advanced cutaneous melanoma, whereas no significant difference in serum sCD163 levels was seen among patients with advanced mucosal melanoma (Figure [2A](#F2){ref-type="fig"}). Increases in serum sCD163 and efficacy at 3 months after the first administration of nivolumab in each patient are described in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}. The thresholds for sCD163 change between day 42 and day 0 to distinguish responders from non-responders were respectively 3.07 ± 0.07 ng/mL and 0.47 ± 0.05 ng/mL in cutaneous and non-cutaneous melanoma. In the cutaneous melanoma cohort, the mean change ratio in sCD163 serum level was 144.6% for those patients showing objective response, compared to 101.0% for non-responders (Table [1](#T1){ref-type="table"}). In the mucosal melanoma cohort, the mean change ratio in sCD163 serum level was 84.1% for those patients showing objective response, and 122.3% for non-responders (Table [2](#T2){ref-type="table"}). The threshold for increased serum sCD163 in cutaneous melanoma was 3.07 ± 0.07 ng/mL, whereas that in non-cutaneous melanoma was 0.47 ± 0.05 ng/mL. The sensitivity and specificity of serum sCD163 in cutaneous melanoma were 84.6 and 87.0%, respectively (*p* = 0.0030; Figure [1B](#F1){ref-type="fig"}), whereas the sensitivity and specificity of serum sCD163 in non-cutaneous melanoma were 100 and 66.7%, respectively (*p* = 0.3154; Figure [2B](#F2){ref-type="fig"}).

![Serum levels of sCD163 and ROC curve in cutaneous melanoma. Serum level changes of sCD163 in each patient (*n* = 59) **(A)** on day 42. The ROC curve was applied to calculate cut-offs for sCD163 serum levels and AUC **(B)**. Cut-offs were determined to distinguish responders from nonresponders using Youden\'s index.](fonc-08-00530-g0001){#F1}

![Serum levels of sCD163 and ROC curve in non-cutaneous melanoma. Serum level changes of sCD163 in each patient (*n* = 16) **(A)** on day 42. The ROC curve was applied to calculate cut-offs for sCD163 serum levels and AUC **(B)**. Cut-offs were determined to distinguish responders from nonresponders using Youden\'s index.](fonc-08-00530-g0002){#F2}

Discussion {#s4}
==========

Because nivolumab shows higher efficacy than other anti-melanoma drugs (e.g., ipilimumab and dacarbazine) ([@B1], [@B17]), and induces a longer duration of anti-tumor response than BRAF/MEK inhibitors (e.g., vemurafenib, dabrafenib, trametinib) ([@B18], [@B19]), oncologists have been particularly interested in combining nivolumab with agents that enhance anti-tumor immune responses in patients with metastatic melanoma ([@B1]--[@B3], [@B20]). The efficacy of nivolumab appears significantly increased when combined with ipilimumab (57.7%), but the rate of severe treatment-related AEs (Grade 3 or 4) is unfortunately also significantly increased with this particular combination (59.0%) ([@B1], [@B2]). To avoid severe AEs caused by ipilimumab, predictive biomarkers are needed to evaluate the efficacy of nivolumab monotherapy at 2--3 months after first administration, to prepare for any planned switch from nivolumab to ipilimumab.

CD163 is a member of the scavenger receptor cysteine-rich family, and is exclusively expressed on cells of the monocyte/macrophage lineage ([@B15]). As previously reported, in metastatic melanoma, a substantial number of CD163^+^ TAMs are present in metastatic melanoma and are activated by stromal factors, leading to an increase in serum levels of sCD163 as a result of proteolytic shedding ([@B21]--[@B23]). In addition, Jensen et al. ([@B21]) previously reported sCD163 and CD163^+^ TAMs as a prognostic marker for early-stage cutaneous melanoma. Notably, as Gordon et al. ([@B14]) reported, PD-1 expression is a key factor in maintaining TAMs as M2-polarized, and blockade of PD-1/PD-L1 leads to conversion of TAMs into M1-polarized activated macrophages. Because TAMs in melanoma comprise a heterogeneous, mainly immunosuppressive population ([@B9], [@B23]), and because repolarization of TAMs into the activated subtype by immunomodulatory drugs has been reported to significantly suppress melanoma growth in a spontaneous mouse melanoma model ([@B8]), we hypothesized that one of the targets for nivolumab in melanoma is activated CD163^+^ TAMs.

To prove our hypothesis, we analyzed serum levels of sCD163 in 59 cases of advanced cutaneous melanoma and 16 cases of advanced mucosal melanoma treated with nivolumab. Serum levels of sCD163 were significantly increased 6 weeks after initial administration of nivolumab in the response group compared to the non-response group in cutaneous melanoma. In contrast, no significant difference between nivolumab responders and non-responders was seen for non-cutaneous melanoma. Interestingly, in non-cutaneous melanoma, serum levels of sCD163 in non-responders tended to be even higher than those in responders. This discrepancy might be explained by differences in cancer stroma that could stimulate TAMs in the tumor microenvironment of each organ. Such studies should be performed in the future.

According to the present results, sCD163 may represent a predictive biomarker for evaluating the efficacy of nivolumab at 3 months after first administration for advanced cutaneous melanoma. Because sequential administration of ipilimumab followed by nivolumab is only effective for advanced melanoma before the melanoma develops tolerance for nivolumab ([@B7]), and administration of ipilimumab leads to the development of irAEs more frequently than nivolumab ([@B2], [@B3]), predicting the efficacy of nivolumab before first tumor estimation is crucial to determining whether the patient will successfully adapt to the planned switch from nivolumab to ipilimumab therapy. The present study suggested that sCD163 may be a useful biomarker for the selection of those cutaneous melanoma patients most likely to benefit from anti-melanoma immunotherapy using nivolumab and ipilimumab. Because this was a pilot study, future independent studies with larger patient cohorts are needed to confirm our findings.
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###### 

Serum levels of sCD163 at day 0 in patients with cutaneous and non-cutaneous melanoma. Mean serum levels of sCD163 in responders (*n* = 13) and non-responders (*n* = 46) at day 0 **(A)**. Mean serum levels of sCD163 in responders (*n* = 4) and non-responders (*n* = 12) at day 0 **(B)** n.s, not significant.

###### 

Click here for additional data file.
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